Regarding the clinical implication of three markers, we suggested SIRT-3 and HIF-1α as predictors of prognosis in early-stage HCC patients, and p-mTOR as a promising therapeutic target for the treatment of advanced-stage HCC. The gene discussed is SIRT3; the disease is hepatocellular carcinoma.